Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 4/2014

01-12-2014 | Management of Menopause (K-E Huang, Section Editor)

Primary Ovarian Insufficiency

Authors: Rodney J. Baber, Michele Kwik

Published in: Current Obstetrics and Gynecology Reports | Issue 4/2014

Login to get access

Abstract

Primary ovarian insufficiency (POI) is a syndrome of amenorrhoea, sex steroid deficiency, and elevated gonadotropins in a woman aged more than two standard deviations below the mean age for menopause estimated for her reference population. In practical terms, it occurs spontaneously in 1 % of women before the age of 40 years. Apart from idiopathic POI, many women will have impaired ovarian function by age 40 years as a consequence of surgery, chemotherapy, or radiotherapy. Of identifiable causes of POI, the most common are concurrent autoimmune diseases such as thyroid and adrenal disease, and chromosomal abnormalities such as Turner syndrome and Fragile X syndrome. Women with POI have an increased risk of heart disease, osteoporosis, stroke, cognitive impairment, and premature death. These risks appear to be greater following a surgical menopause. POI is associated with an increased prevalence of anxiety, depression, and loss of self-esteem. Whilst most women with POI will remain infertile following their diagnosis, many will menstruate again and 5 – 10 % will become pregnant. The keys to good management are a multidisciplinary approach, careful long-term follow–up, and appropriate use of hormone replacement therapy.
Literature
1.
2.
Coulam CB et al. Empty follicle syndrome. Fertil Steril. 1986;46:1153–5.PubMed
3.•
Cooper AR et al. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril. 2011;95:1890–7. This article is a good summary on POI.PubMedCentralPubMedCrossRef
4.
5.•
Rafique S et al. A new approach to primary ovarian insufficiency. Obstet Gynecol Clin N Am. 2012;39:567–86. This article is a good summary on POI.CrossRef
6.
Persani L et al. Genes involved in human premature ovarian failure. J Mol Endocrinol. 2010;45:257–79.PubMedCrossRef
7.
8.•
Cox L, Liu J. Primary ovarian insufficiency; and update. Int J Women's Health. 2014;6:235–43. This article is a good summary on POI.
9.
Cate RL et al. Isolation of bovine and human genes for mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685–98.PubMedCrossRef
10.
Kevenaar ME et al. Serum AMH levels reflect the size of the primordial follicle pool in mice. Endocrinology. 2006;147:3228–34.PubMedCrossRef
11.•
Dewailly D et al. The physiology and clinical utility of AMH in women. Hum Reprod Update. 2014;20:370–85. This article is a good summary on AMH and its clinical application.PubMedCrossRef
12.
Dillon K et al. Pretreatment levels of AMH determine post therapy rates of recovery of ovarian reserve in women undergoing chemotherapy. Fertil Steril. 2013;99:477–83.PubMedCentralPubMedCrossRef
13.
Dolleman M et al. AMH is a more accurate predictor of an individual's time to menopause than mother’s age at menopause. Hum Reprod. 2014;29:584–91.PubMedCrossRef
14.
Sklavos MM et al. AMH deficiency in females with Fanconi anaemia. J Clin Endocrinol Metab. 2014;99(5):1608–14.PubMedCrossRef
15.
Spencer JB et al. Modifiers of ovarian function in girls and young women with classic galactosemia. J Clin Endocrinol Metab. 2013;98:1257–65.CrossRef
16.
17.
18.
Allen EG et al. Examination of reproductive milestones amongst women who carry the FMR1 pre mutation. Hum Reprod. 2007;22:2142–52.PubMedCrossRef
19.
Willemsen R et al. CGG repeats in the FMR 1 pre mutation. Size Matter Clin Genet. 2011;0:214–25.CrossRef
20.
21.
22.
Waad-Allah S et al. CAH due to 17 alpha hydroxylase deficiency. Oman Med J. 2014;29:55–9.CrossRef
23.
24.
25.
Conway G et al. Characterisation of idiopathic premature ovarian failure. Fertil Steril. 1996;65:337–14.PubMed
26.
Alper M, Garner P. Premature ovarian failure: its relationship to autoimmune disease. Obstet Gynecol. 1985;66:27–30.PubMed
27.
Rebar R. Mechanisms of premature menopause. Endocrinol Metab Clin N Am. 2005;34:923–33.CrossRef
28.
Kokcu A. Premature ovarian failure from a current perspective. Gynecol Endocrinol. 2010;26:555–62.PubMedCrossRef
29.
Ohl J et al. Alterations in ovarian reserve tests in HIV infected women. Gynecol Obstet Fertil. 2010;38:313–7.PubMedCrossRef
30.
Siddle N et al. The effect of hysterectomy on age at ovarian failure. Fertil Steril. 1987;47:94–100.PubMed
31.
32.
33.
Busacca M et al. Post surgical ovarian failure after laparoscopic removal of endometriomas. Am J Obstet Gynecol. 2006;195:421–5.PubMedCrossRef
34.
Raffi F et al. The impact of removal of ovarian endometrioma on ovarian reserve. J Clin Endocrinol Metab. 2012;97:3146–54.PubMedCrossRef
35.
Bjelland EK et al. Is unilateral oophorectomy associated with age at menopause? Hum Reprod. 2014;29:835–41.PubMedCrossRef
36.•
Baber R. Primary ovarian insufficiency. Med Today. 2014;15:73–5. This article is a good summary on POI.
37.•
Fleischer RT et al. The effect of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv. 2011;66:248–54. This article is a good summary on the effect of chemoradiation therapy on fertility.PubMedCrossRef
38.
Barameh S et al. Ovarian transposition prior to pelvic irradiation. J Obstet Gynaecol Res. 2013;39:1533–7.CrossRef
39.
Constine LS et al. Hypothalamic pituitary dysfunction after irradiation for brain tumours. N Engl J Med. 1993;328:87–94.PubMedCrossRef
40.
Maltaris T et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol. 2007;130:148–55.PubMedCrossRef
41.
Wallace WH et al. Fertility preservation for young people with cancer; who is at risk and what can be offered. Lancet Oncol. 2005;6:209–18.PubMedCrossRef
42.
43.
Richardson RB et al. Greater organ involution in highly proliferative tissues is associated with the early onset of and accelerated ageing in humans. Exp Gerontol. 2014;55:80–91.PubMedCrossRef
44.
Alzubaidi NHH et al. Meeting the needs of your women with secondary amenorrhoea and premature ovarian failure. Obstet Gynecol. 2002;99:720–5.PubMedCrossRef
45.
Schmidt PJ et al. Shyness, social anxiety and impaired self esteem in women with turner syndrome and POI. JAMA. 2006;295:1374–6.PubMedCrossRef
46.
Van Kasteren Y, Shoemaker J. Premature ovarian failure. A systematic review of therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5:483–92.PubMedCrossRef
47.
48.
Baker V. Life plans and family building options for women with POI. Semin Reprod Med. 2011;29:362–72.PubMedCrossRef
49.
Ben-Nagy J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric. 2014;17(3):242–6.CrossRef
50.•
The Practice Committee of the American Society of Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100:1214–23. This article is a good reference for fertility preservation strategies.CrossRef
51.
Garcia-Velasco J. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril. 2012;97:527–8.PubMedCrossRef
52.
Cobo A et al. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239–46.PubMedCrossRef
53.
Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause. 2007;14:572–9.PubMedCrossRef
54.
55.
Bove R et al. Age at surgical menopause influences cognitive decline and Alzheimers pathology in older women. Neurology. 2014;21:222–9.CrossRef
56.
Rocca W et al. Oophorectomy, menopause, estrogen treatment and cognitive ageing. Clinical evidence for a window of opportunity. Brain Res. 2011;16:188–98.CrossRef
57.
Ossewarde M et al. Age at menopause, cause specific mortality and total life expectancy. Epidemiology. 2005;16:556–62.CrossRef
58.
Mondul A et al. Age at natural menopause and cause specific mortality. Am J Epidemiol. 2005;162:1089–97.PubMedCrossRef
59.•
Wellons M et al. Early menopause predicts increased risk of coronary heart disease and stroke. Menopause. 2012;19:1081–7. This article is a good reference for POI and cardiovascular disease.PubMedCentralPubMedCrossRef
60.
Atsma F et al. Post menopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13:265–79.PubMedCrossRef
61.
62.•
Rocca W et al. Premature menopause or early menopause and risk of stroke. Menopause. 2012;19:272–7. This article is a good reference for POI and stroke.PubMedCentralPubMedCrossRef
63.
Anasti JN et al. Bone loss in young women with karyotypically normal premature ovarian failure. Obstet Gynecol. 1998;91:12–5.PubMedCrossRef
64.
Pal L, Santoro N. Premature ovarian failure: discordance between somatic and reproductive ageing. Ageing Res Rev. 2002;1:413–23.PubMedCrossRef
65.
Luborsky JL et al. Premature menopause in a multiethnic study of the menopause transition. Hum Reprod. 2002;18:199–206.CrossRef
66.
Shuster L et al. Prophylactic oophorectomy in premenopausal women and long term health - a review. Menopause Int. 2008;14:111–6.PubMedCentralPubMed
67.
68.
Mishell DR et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol. 1971;111:60–5.PubMed
69.
Scarabin P et al. Differential association of oral and transdermal estrogen therapy with venous thromboembolism risk. Lancet. 2003;362:428–32.PubMedCrossRef
70.
Gibbons WR et al. Biochemical and histological effects of estrogen and progestogen therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1986;154:456–61.PubMedCrossRef
71.
Fournier A et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–11.PubMedCentralPubMedCrossRef
72.
Rossouw J et al. Risks and benefits of estrogen plus progestin in health post menopausal women: principal results from the Women's Health Initiative RCT. JAMA. 2002;288:321–33.PubMedCrossRef
73.•
de Villiers T et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16:203–4. This article is a good reference for hormone replacement therapy.PubMedCrossRef
74.
Davis SR, Burger HG. The role of androgen therapy. Best Pract Res Clin Endocrinol Metab. 2003;17:165–75.PubMedCrossRef
75.
Kalantaridou S et al. Testosterone deficiency in young women with 46XX premature ovarian failure. Fertil Steril. 2006;86:1475–82.PubMedCrossRef
76.
Guerrieri GM et al. Effects of physiological testosterone therapy on quality of life, self esteem and mood in women with premature ovarian insufficiency. Menopause. 2014;21:1–9.CrossRef
77.
Davis SR, Worsley R. Androgen treatment of post menopausal women. J Steroid Biochem Mol Biol. 2014;142:107–14.PubMedCrossRef
78.
Baber R, Kwik M. Therapy for menopausal symptoms during and after breast cancer: safety considerations. Drug Saf. 2005;28:1085–2000.PubMedCrossRef
79.
Metadata
Title
Primary Ovarian Insufficiency
Authors
Rodney J. Baber
Michele Kwik
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 4/2014
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-014-0094-7

Other articles of this Issue 4/2014

Current Obstetrics and Gynecology Reports 4/2014 Go to the issue

Minimally Invasive Gynecologic Surgery (A Fader, Section Editor)

Laparoscopic Management of Pelvic Masses in Pregnancy

Management of Menopause (K-E Huang, Section Editor)

DHEA supplementation in Menopause

Management of Menopause (K-E Huang, Section Editor)

Menopausal Hormonal Therapy and Cardiovascular Disease

Management of Menopause (K-E Huang, Section Editor)

How to Prescribe MHT According to the Risk of Breast Cancer

Minimally Invasive Gynecologic Surgery (A Fader, Section Editor)

Robotic Surgery in Gynecologic Oncology: Updates and Innovations

Minimally Invasive Gynecologic Surgery (A Fader, Section Editor)

Laparoscopic Versus Robotic Sacrocolpopexy: Outcomes and Costs